1. From the Division of Oncology Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville; Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; and GlaxoSmithKline, Philadelphia, PA